X4 Pharmaceuticals (XFOR) Competitors $3.21 +0.22 (+7.36%) Closing price 04:00 PM EasternExtended Trading$3.10 -0.12 (-3.58%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XFOR vs. SCLX, CABA, LFVN, MIST, AVTX, THTX, CHRS, GLSI, CLLS, and CYBNShould you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Scilex (SCLX), Cabaletta Bio (CABA), Lifevantage (LFVN), Milestone Pharmaceuticals (MIST), Avalo Therapeutics (AVTX), Theratechnologies (THTX), Coherus Oncology (CHRS), Greenwich LifeSciences (GLSI), Cellectis (CLLS), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry. X4 Pharmaceuticals vs. Its Competitors Scilex Cabaletta Bio Lifevantage Milestone Pharmaceuticals Avalo Therapeutics Theratechnologies Coherus Oncology Greenwich LifeSciences Cellectis Cybin Scilex (NASDAQ:SCLX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment. Does the media prefer SCLX or XFOR? In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Scilex. MarketBeat recorded 3 mentions for X4 Pharmaceuticals and 2 mentions for Scilex. Scilex's average media sentiment score of 1.78 beat X4 Pharmaceuticals' score of 1.16 indicating that Scilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scilex 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive X4 Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SCLX or XFOR more profitable? Scilex has a net margin of -179.12% compared to X4 Pharmaceuticals' net margin of -311.15%. Scilex's return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Scilex-179.12% N/A -109.95% X4 Pharmaceuticals -311.15%-375.31%-72.87% Do analysts recommend SCLX or XFOR? Scilex currently has a consensus target price of $455.00, indicating a potential upside of 1,916.84%. X4 Pharmaceuticals has a consensus target price of $34.17, indicating a potential upside of 964.38%. Given Scilex's higher possible upside, equities research analysts plainly believe Scilex is more favorable than X4 Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in SCLX or XFOR? 69.7% of Scilex shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 7.9% of Scilex shares are held by company insiders. Comparatively, 2.4% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, SCLX or XFOR? Scilex has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Which has preferable valuation and earnings, SCLX or XFOR? X4 Pharmaceuticals has lower revenue, but higher earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScilex$56.59M2.77-$72.81M-$29.02-0.78X4 Pharmaceuticals$32.77M1.12-$37.45M-$14.84-0.22 SummaryScilex and X4 Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XFOR vs. The Competition Export to ExcelMetricX4 PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.62M$3.09B$5.70B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.2221.3075.8626.51Price / Sales1.12380.87491.12165.50Price / CashN/A44.4425.8129.89Price / Book0.829.6112.846.32Net Income-$37.45M-$53.28M$3.28B$270.51M7 Day Performance-2.13%0.32%0.22%2.15%1 Month Performance12.63%4.59%4.61%6.35%1 Year Performance-83.85%9.24%68.33%25.49% X4 Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XFORX4 Pharmaceuticals4.6864 of 5 stars$3.21+7.4%$34.17+964.4%-86.0%$36.62M$32.77M-0.2280Positive NewsShort Interest ↓Gap UpSCLXScilex2.2004 of 5 stars$22.17-2.8%$455.00+1,952.3%-36.1%$158.59M$56.59M-0.7680Positive NewsCABACabaletta Bio3.0584 of 5 stars$1.68-1.2%$14.50+763.1%-53.5%$155.49MN/A-0.6250Positive NewsLFVNLifevantage3.9973 of 5 stars$11.44-5.5%$30.50+166.6%+1.7%$153.69M$228.53M15.46260High Trading VolumeMISTMilestone Pharmaceuticals2.4456 of 5 stars$1.75-2.8%$5.00+185.7%+29.6%$152.99M$1M-2.0830Positive NewsAVTXAvalo Therapeutics3.9005 of 5 stars$11.41-1.6%$30.00+162.9%+12.9%$152.57M$440K0.0040News CoverageShort Interest ↓Gap UpTHTXTheratechnologiesN/A$3.27flatN/A+143.7%$150.35M$85.87M-17.21140Short Interest ↓CHRSCoherus Oncology4.2001 of 5 stars$1.37+6.2%$4.51+229.4%-2.3%$149.93M$272.21M0.88330GLSIGreenwich LifeSciences1.5378 of 5 stars$11.17+2.2%$42.00+276.0%-21.8%$148.98MN/A-8.213CLLSCellectis3.3518 of 5 stars$2.74+2.2%$4.00+46.0%+32.9%$148.96M$49.22M-3.34290Positive NewsShort Interest ↓Gap UpCYBNCybin2.1401 of 5 stars$6.27-6.8%$85.00+1,255.7%N/A$147.91MN/A-1.4350 Related Companies and Tools Related Companies SCLX Competitors CABA Competitors LFVN Competitors MIST Competitors AVTX Competitors THTX Competitors CHRS Competitors GLSI Competitors CLLS Competitors CYBN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XFOR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XFOR Stock Alerts